Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it has confidentially submitted a draft registration statement …